Original paper
A 3-Part Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DSP-6952 in Healthy Japanese Subjects and Those With ≤3 Spontaneous Bowel Movements per Week., Yumizaki T, Maeda M, Fujita T, Kakuyama H, Kumagai Y, Clin Pharmacol Drug Dev, 9(3), 353-365, Apr. 2020
Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment., Itou M, Fujita T, Inoue K, Uchida N, Takagaki T, Ishii D, Kakuyama H., J Clin Pharmacol., 60(10), 1397-1403, Oct. 2020
5-HT2B Receptors-triggered Serotonin Release from Guinea-pig Isolated Colonic Mucosa:a Role of Endogenous Peptide YY, Ken Kojima, Shu-ichi Kojima, Tomoe Fujita, Dokkyo Journal of Medical Sciences, 48(2), 81-86, 25 Jul. 2021
Effect of In-vivo Administration of Nafamostat on the Onset of Renal Hyperkalemia and Association of Urine Kallikrein in Rat, Teppei Yamada, Hiromichi Kaneko, Chihiro Inose, Sawako Tanaka-Nakadate, Hiroki Hanawa, Shinsuke Hamaguchi, Shigeki Yamaguchi, Tomoe Fujita, Dokkyo Journal of Medical Sciences, 48(1), 33-42, 25 Mar. 2021
An exploratory study on the development of drug-induced renal hyperpotassemia in general anesthetized rats., Hanawa H, Yamada T, Tanaka-Nakadate S, Yamaguchi S, Hamaguchi S, Fujita T, Dokkyo Medical Journal, 2(2), 148-157, 25 Jun. 2023
Development of a Young Rat Hyperkalemia Model with Decreased Renal Excretion of Potassium, Takagi Y, Yamada T, Tanaka-Nakadate S, Fujita T, Yoshihara S., Dokkyo Medical Journal, 2(2), 138-147, 25 Jun. 2023
Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies., Kumagai Y, Fujita T, Maeda M, Yamamoto A, Amano H, Br J Clin Pharmacol, 1-12, 14 Mar. 2025
Involvement of the renal kallikrein–kinin system in the diuretic action of a thiazide using a crossover design in rats: an exploratory study. Journal of Pharmacology and Pharmacotherapeutics., Fujita T, Kamata M, Kumagai Y, Majima M., Journal of Pharmacology and Pharmacotherapeutics, 18 Dec. 2025